William Blair Equities Analysts Reduce Earnings Estimates for Danaher Co. (NYSE:DHR)

Danaher Co. (NYSE:DHR) – Equities researchers at William Blair lowered their Q2 2024 earnings per share estimates for Danaher in a research report issued on Wednesday, April 24th. William Blair analyst M. Larew now anticipates that the conglomerate will post earnings of $1.56 per share for the quarter, down from their prior estimate of $1.61. The consensus estimate for Danaher’s current full-year earnings is $7.64 per share. William Blair also issued estimates for Danaher’s Q3 2024 earnings at $1.73 EPS, Q4 2024 earnings at $2.45 EPS, Q1 2025 earnings at $2.29 EPS, Q2 2025 earnings at $1.86 EPS, Q3 2025 earnings at $1.98 EPS, Q4 2025 earnings at $2.77 EPS and FY2025 earnings at $8.90 EPS.

A number of other equities research analysts have also recently commented on DHR. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Citigroup boosted their price objective on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research report on Wednesday. Robert W. Baird boosted their target price on Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a research note on Wednesday. KeyCorp boosted their target price on Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a research note on Thursday, February 1st. Finally, Raymond James boosted their target price on Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. Six investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and a consensus price target of $270.00.

Danaher Trading Up 0.3 %

Shares of DHR stock opened at $246.45 on Thursday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.37 and a current ratio of 1.85. Danaher has a fifty-two week low of $182.09 and a fifty-two week high of $259.00. The stock has a 50 day simple moving average of $248.87 and a two-hundred day simple moving average of $231.08. The company has a market cap of $182.54 billion, a P/E ratio of 41.77, a PEG ratio of 4.19 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.62 billion. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The firm’s revenue for the quarter was down 2.6% on a year-over-year basis. During the same period in the previous year, the company posted $2.36 earnings per share.

Danaher Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, April 26th. Shareholders of record on Thursday, March 28th were paid a $0.27 dividend. This is a positive change from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. The ex-dividend date of this dividend was Wednesday, March 27th. Danaher’s dividend payout ratio is currently 18.31%.

Insider Transactions at Danaher

In related news, SVP Georgeann Couchara sold 2,622 shares of the business’s stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total value of $636,280.74. Following the completion of the sale, the senior vice president now owns 4,244 shares in the company, valued at approximately $1,029,891.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Walter G. Lohr sold 3,289 shares of Danaher stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $251.15, for a total value of $826,032.35. Following the transaction, the director now owns 14,129 shares in the company, valued at approximately $3,548,498.35. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Georgeann Couchara sold 2,622 shares of Danaher stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total transaction of $636,280.74. Following the completion of the transaction, the senior vice president now owns 4,244 shares in the company, valued at approximately $1,029,891.48. The disclosure for this sale can be found here. In the last three months, insiders sold 106,565 shares of company stock worth $26,641,364. 11.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Danaher

A number of large investors have recently added to or reduced their stakes in DHR. Tsfg LLC increased its position in shares of Danaher by 733.3% in the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after acquiring an additional 88 shares during the period. Cape Investment Advisory Inc. purchased a new position in shares of Danaher in the fourth quarter valued at about $25,000. BKM Wealth Management LLC purchased a new position in shares of Danaher in the fourth quarter valued at about $27,000. Redmont Wealth Advisors LLC purchased a new position in shares of Danaher in the first quarter valued at about $30,000. Finally, Wetzel Investment Advisors Inc. purchased a new position in shares of Danaher in the fourth quarter valued at about $29,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.